Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http://www.fivestarequities.com/ and get exclusive access to our numerous stock reports.
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) shares dropped 19.79 percent to close at $1.50 a share Tuesday. The stock traded between $1.35 and $1.57 on volume of 1.26 million shares traded. The company announced that it will be delaying its submission of a new drug application to the FDA after its drug deterrent tests yielded little results. Shares of Acura Pharmaceuticals have fallen approximately 32.0 percent year-to-date.
Get more information on Acura Pharmaceuticals and free access to the in-depth equity report at:
Akorn, Inc. (NASDAQ: AKRX) shares spiked 9.61 percent to close at $18.02 a share Tuesday. The stock traded between $17.87 and $18.98 on volume of 4.60 million shares traded. The company announced that it has acquired Hi-Tech Pharmacal Co., Inc. for $640 million in cash. Shares of Akorn have gained approximately 35.0 percent year-to-date.
Get more information on Akorn and free access to the in-depth equity report at:
Catalyst Pharmaceutical Partners, Inc. (NASDAQ: CPRX) shares soared 41.55 percent to close at $2.01 a share Tuesday. The stock traded between $1.95 and $2.50 on volume of 18.30 million shares traded. The company announced that it has received "Breakthrough Therapy Designation" from the FDA for Firdapse for the treatment of patients with Lambert-Eaton Myasthenic Syndrome.
Get more information on Catalyst Pharmaceutical and free access to the in-depth equity report at:
SYNNEX Corporation (NYSE: SNX) shares declined 5.84 percent to close at $47.74 a share Tuesday. The stock traded between $47.45 and $49.12 on volume of 282,015 shares traded. The company reported revenues for the fiscal fourth quarter declined $26.6 million, or 5.0 percent, when compared to a year ago. Shares of SYNNEX have gained approximately 38.0 percent year-to-date.
Get more information on SYNNEX and free access to the in-depth equity report at:
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.
Five Star Equities